- Home
- MGEE vs GH Comparison
MGEE vs GH Comparison
Compare MGEE & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGEE
- GH
- Stock Information
- Founded
- MGEE 1855
- GH 2011
- Country
- MGEE United States
- GH United States
- Employees
- MGEE N/A
- GH N/A
- Industry
- MGEE Electric Utilities: Central
- GH Medical Specialities
- Sector
- MGEE Energy
- GH Health Care
- Exchange
- MGEE Nasdaq
- GH Nasdaq
- Market Cap
- MGEE 3.8B
- GH 4.3B
- IPO Year
- MGEE N/A
- GH 2018
- Fundamental
- Price
- MGEE $94.46
- GH $31.83
- Analyst Decision
- MGEE Sell
- GH Strong Buy
- Analyst Count
- MGEE 1
- GH 14
- Target Price
- MGEE $74.00
- GH $39.93
- AVG Volume (30 Days)
- MGEE 199.8K
- GH 1.6M
- Earning Date
- MGEE 02-19-2025
- GH 11-06-2024
- Dividend Yield
- MGEE 1.91%
- GH N/A
- EPS Growth
- MGEE N/A
- GH N/A
- EPS
- MGEE 3.27
- GH N/A
- Revenue
- MGEE $653,681,000.00
- GH $692,256,000.00
- Revenue This Year
- MGEE $2.14
- GH $32.23
- Revenue Next Year
- MGEE $4.75
- GH $16.90
- P/E Ratio
- MGEE $28.89
- GH N/A
- Revenue Growth
- MGEE N/A
- GH 29.20
- 52 Week Low
- MGEE $61.94
- GH $15.81
- 52 Week High
- MGEE $109.22
- GH $38.53
- Technical
- Relative Strength Index (RSI)
- MGEE 36.58
- GH 45.64
- Support Level
- MGEE $91.94
- GH $34.20
- Resistance Level
- MGEE $96.45
- GH $36.24
- Average True Range (ATR)
- MGEE 2.70
- GH 1.70
- MACD
- MGEE -1.17
- GH -0.92
- Stochastic Oscillator
- MGEE 18.17
- GH 15.98
About MGEE MGE Energy Inc
MGE Energy provides electric service to 161,000 customers and natural gas service to 173,000 customers in Madison, Wisconsin, and surrounding areas. Nearly 90% of customers are residential. The company also owns a 3.6% stake in American Transmission Co. MGE owns interests in two coal power plants that earn guaranteed fixed rates of return, contributing about 20% of earnings. MGE's generation mix is 40% coal, 21% renewable energy, 17% natural gas, and third-party purchased power.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.